Sep 18, 2020 10:38am EDT Medexus Engages Adelaide Capital for Investor Relations Services and Reports Annual Meeting Results
Sep 10, 2020 9:20am EDT Medexus Reports Health Canada Approval of Gleolan® (5-ALA) for Use in Guided Surgical Resection of High-Grade Gliomas
Aug 24, 2020 7:57pm EDT Medexus Announces Move to a Virtual Meeting for 2020 AGM and Equity Incentive Grants
Aug 24, 2020 8:00am EDT Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Inclusion on Quebec’s RAMQ List of Medications (Basic Plan and Institutions)
Aug 11, 2020 5:19pm EDT Medexus Pharmaceuticals Reports Record Revenue of $27.5 Million and $5.0 Million of Adjusted EBITDA* for the First Quarter of Fiscal 2021
Aug 11, 2020 8:30am EDT Medexus Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference on August 12th
